Common questions about Metoject (FAQ)
Q: Can I drink alcohol while I am using Metoject?
A: Regulatory documents state that alcohol abuse is a formal contraindication for using this medicine. The medicine's official labeling advises against concomitant use with alcohol because there is a documented increased risk of liver toxicity (hepatotoxicity) when these substances are combined.
Q: Are there any specific vitamins or supplements I should avoid when using Metoject?
A: Official guidance emphasizes that folic acid or folinic acid supplements should only be taken as specifically instructed by a healthcare provider. Taking them outside of guidance could interfere with the therapeutic effects of the medicine. Official documentation for the medicine does not typically list specific restrictions for most other common vitamins.
Q: Can Metoject interact with common pain relievers like ibuprofen or naproxen?
A: Yes, this medicine is known to interact with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen or naproxen. These pain relievers may increase the concentration of the medicine in the blood by reducing how quickly the kidneys can clear it. This interaction may lead to increased plasma concentrations, which raises the risk of severe side effects.
Q: Can Metoject interact with antibiotics?
A: The official interaction profile indicates that certain antibiotics, particularly those with antifolate properties like trimethoprim/sulfamethoxazole, can dangerously increase the risk of toxicity. Other types of antibiotics, such as penicillins, are also noted to require caution when used alongside this medicine.
Q: Can Metoject cause sun sensitivity?
A: Official information mentions that this medicine may make your skin more sensitive to sunlight, a condition known as photosensitivity. Patients are advised to use sun protection, such as wearing sunscreen, eye protection, and a hat, or avoiding sunlamps and tanning beds.
Q: Can Metoject cause problems with my liver long-term?
A: Liver toxicity, which can include conditions like fibrosis and cirrhosis, is a documented risk associated with long-term use of this medicine. The risk of these problems is noted to increase with the cumulative exposure over time. For this reason, mandatory, close monitoring of liver function is required for all patients.
Q: Can Metoject cause fatigue or tiredness?
A: Yes, fatigue and tiredness are listed in regulatory documents as a common side effect of this medicine. Common means this effect is experienced by ge 1/100 to < 1/10 (1% to 10%) of patients.
Q: Do people who take Metoject need special blood tests?
A: Yes, the regulatory profile confirms the requirement for mandatory, close monitoring during treatment. This monitoring includes routine testing of complete blood counts as well as liver and kidney function to help observe for early signs of toxicity.
Q: Why do some people need to take folic acid with Metoject?
A: Folic acid or folinic acid is often prescribed for use alongside this medicine to reduce the chance of developing certain side effects, such as mouth sores or digestive issues. This supplementation is intended to be taken only as instructed by a healthcare provider.
Q: Does Metoject stop working over time?
A: Studies and official information indicate that for patients with Rheumatoid Arthritis, an initial clinical improvement is typically maintained for at least two years with continued therapy. Official documents state that if the medicine is discontinued, the symptoms of the treated condition usually worsen within three to six weeks.
Q: What's the main difference between Metoject and methotrexate tablets?
A: Metoject is an injection, and the key difference compared to methotrexate tablets is the way it is absorbed into the body. The injectable form is more consistently and reliably absorbed than the oral tablet. This better absorption may be why some patients experience fewer gastrointestinal side effects and a better overall response.
Q: Can Metoject be used for conditions other than rheumatoid arthritis?
A: Yes, regulatory documents indicate that the medicine is approved for several other inflammatory conditions. These include polyarthritic forms of severe juvenile idiopathic arthritis, severe recalcitrant disabling psoriasis, psoriatic arthritis, and mild to moderate Crohn's disease in adults.
Q: Is it normal to feel a little nauseous after taking Metoject?
A: Yes, nausea is classified as a very common side effect in official regulatory documents. Very common means this effect is experienced by ge 1/10 (10% or more) of patients.
Q: How long does it typically take before I notice Metoject starting to work?
A: According to official product information, the therapeutic response usually begins within three to six weeks of starting treatment. The full benefit of the medicine may be experienced over a longer period.
Q: Does Metoject affect my immune system or make me more likely to get sick?
A: The medicine is classified as an immunosuppressive agent, meaning it works by modulating the activity of the immune system. This suppression can increase the risk of developing serious infections.
Q: If I miss my weekly dose of Metoject, what should I do?
A: Because the medicine is administered on a strict weekly schedule, regulatory guidance advises patients to contact their healthcare provider immediately for instructions about when to take their next dose. This ensures the correct, fixed schedule is maintained.
Q: Does Metoject need to be kept refrigerated?
A: Official labeling states that the medicine should typically be stored below 25 C and should not be frozen. The exact temperature range is documented in the product information.
Q: Can Metoject affect fertility in men or women?
A: Official information reports that the medicine may affect the production of sperm and eggs. This can lead to oligospermia (low sperm count) in men and menstrual dysfunction or amenorrhoea (absence of periods) in women. These effects are often described as reversible upon discontinuation of the medicine.
Q: Are there restrictions on getting vaccines while on Metoject?
A: Yes, regulatory documents state that concurrent vaccination with live vaccines is formally contraindicated during treatment. This is due to the risk of an impaired immune response.
Q: What are the most common reasons why Metoject might be stopped?
A: Official documentation indicates the medicine may be stopped for specific adverse events, such as developing a severe infection, liver disease, respiratory disease, or severe bone marrow suppression. Regulatory constraints indicate the medicine must be stopped if a patient is pregnant or planning for pregnancy.
Q: Are there specific foods I should avoid while taking Metoject?
A: Official regulatory documents do not list specific foods that must be avoided, but the consumption of alcohol is strongly advised against due to severe toxicity risks. Some health authorities note that avoiding unpasteurized foods may be advisable to help reduce the risk of infection, due to the medicine's effects.
Q: Does Metoject cause hair thinning or hair loss?
A: Yes, hair loss (alopecia) is classified as a common side effect in official regulatory documents. Common means this effect is experienced by ge 1/100 to < 1/10 (1% to 10%) of patients.
Q: Can I take Metoject if I am pregnant or planning to become pregnant soon?
A: The medicine is formally contraindicated in pregnancy and breastfeeding due to the potential for harm. Women and men of reproductive potential must use effective contraception during and for a specified time after treatment cessation.
Q: How quickly does Metoject leave the body after the last dose?
A: According to the pharmacokinetic properties described in regulatory documents, the elimination half-life of the medicine is typically between three and ten hours. The half-life is a scientific measure that indicates how quickly the body clears the medicine.
Q: Are there documented cases of Metoject causing depression or mood changes?
A: Official information lists psychiatric side effects as documented adverse reactions. Confusion and depression are classified as uncommon side effects (occurring in ge 1/1000 to < 1/100 of patients).
Q: Can Metoject make existing skin problems worse?
A: Official documentation notes that the medicine can cause severe skin reactions. Official guidance notes that due to the potential for severe skin reactions, caution is advised for patients with existing mucosal or skin issues.
Q: What is the typical duration of treatment with Metoject?
A: The optimal duration of therapy is not uniformly defined; however, limited long-term studies indicate that the beneficial effect of the medicine can be maintained for at least two years with continued use. Treatment length is determined by the patient’s response and tolerability.
Q: If I feel well, can I stop taking Metoject?
A: Clinical information indicates that if the medicine is discontinued, the symptoms of the condition being treated may begin to worsen, typically within three to six weeks. Treatment should only be stopped under the guidance of a healthcare provider.
Q: Are there long-term studies on the safety of Metoject?
A: Official documents reference limited long-term studies. These primarily address the maintenance of effect for at least two years and the continued monitoring necessary for long-term risks like liver toxicity.
Q: Is the injection site reaction (redness/soreness) normal after Metoject?
A: Yes, localized reactions at the injection site are classified as a common side effect in official regulatory documents. This can include pain, redness, and swelling in the area where the medicine was injected.
Q: Does Metoject help reduce inflammation quickly?
A: Official product information indicates that the therapeutic response for conditions like Rheumatoid Arthritis usually begins within three to six weeks of starting treatment. This medicine is not intended for immediate pain relief.
Q: Is there a generic version of Metoject available?
A: The active ingredient in Metoject is methotrexate, and methotrexate is widely available as a generic medication. Specific availability may depend on local health regulations and dispensing practices.
